COVID-19 vaccine from China approved by the WHO for emergency use

COVID-19 vaccine from China will soon reach every part of the world as companies export vaccines to many countries, especially Latin America, Asia and Africa, many of which have encountered problems in supplying vaccines developed in the West.

The World Health Organization (WHO) approved the emergency COVID-19 vaccine from China’s state-owned pharmaceutical company Sinopharm on Friday, spurring Beijing’s request for a greater role in world vaccination. COVID-19 vaccine from China was originally developed by non-Western countries approved by the World Health Organization. It has been donated to hundreds of millions of people in China and other countries.

This is also the first time that the World Health Organization has approved the emergency use of China’s infectious disease vaccine. Earlier this week, several WHO experts expressed concern about the quality of the company’s side effects data. The WHO emergency list sends a signal to national regulatory agencies that the product is safe and effective. This means that it can also be included in COVAX.

WHO’s serious effort for covid vaccination

Global vaccination plans, especially for poor countries with supply problems. WHO Director-General Tedros Adhanom Ghebreyesus stated to WHO consultant Bruce Aylward in a briefing: “This expands the range of COVID-19 vaccines that COVAX can purchase and gives countries confidence that they can speed up their own Regulatory approval and import and management of this vaccine.” It should be said how many doses of vaccine it can provide for the plan, but he added: “They are working hard to provide substantial support, provide a large number of doses, of course, and try to get the Chinese to do it at the same time.

Read here: The first vaccine of COVID-19 injected in the US

COVID provides emergency relief: Pfizer-Biotech, AstraZeneca, Johnson & Johnson and Monaco last week developed -19 vaccines last week. This means that the quality, safety, effectiveness and practicality of the Sinopharm CNBG COVID-19 vaccine will meet the requirements of the WHO standard, which will help China become stronger in the global fight against the COVID-19 pandemic. Statement on social media. media.

WHO approves COVID-19 vaccine from China

The decision to approve the Sinopharm vaccine was made by the World Health Organization Technical Advisory Group, which has been meeting since April 26 to review the latest clinical data and industry practices. Tedros said that once approved, the independent Strategic Advisory Expert Group (SAGE) recommends that adults over the age of 18 receive two doses of the Chinese medicine vaccine.

Based on all available data, WHO recommends a two-dose schedule for adults over 18 years of age, with an interval of three to four weeks. … “The vaccine was developed by the Beijing Institute of Biological Products of the Beijing Branch of China National Biotechnology Group. He said that the subsidiary of Sinopharm Group has an effective rate of 79% for people of all ages.

Read here: Pfizer and BioNTech: COVID-19 vaccine provides fruitful results

SAGE Group Chairman Alex Jandro Craviato said: “The information we provide to people over 60 is still very scarce. There is no reason to believe that the vaccine will behave differently in this higher age group. To monitor people over 60 years old, people with underlying diseases and pregnant women after vaccination.

Sinopharm has approved two COVID-19 vaccines in China and has shipped more than 200 million doses overseas, while Sinopharm has shipped 300 million doses to it. Both companies export vaccines to many countries, especially Latin America, Asia and Africa, many of which have encountered problems in supplying vaccines developed in the West. COVID-19 vaccine from China will soon reach every part of the world.

Recent Articles

Related Stories